



NHS Wales shingles vaccination programme Visual aid for Healthcare Professionals

Key changes from 1st September 2023:

This information is for health professionals who are responsible for delivering the NHS shingles vaccination programme across Wales.

Two shingles vaccines are currently available in Wales:



Zostavax® is a live attenuated vaccine, given as **one** dose.



Shingrix® is a recombinant adjuvanted (non-live) subunit vaccine, given as **two** doses.

Which vaccine should individuals receive, and when?

Individuals who are eligible for vaccination should be invited for their vaccination.

From 1st September 2023 to 31st August 2028 (Phase one):

Individual's age on or after 01 September each year from 2023 until 2028	Is the individual severely immunosuppressed?	When will they recieve the Shingrix® vaccine?	
		1st dose	2nd dose
Turned 65 years or 70 years^ (on/after 01 September each year from 2023 to 2028)	No	Aged 65 years Aged 70 years	Between 6 and 12 months following first dose
71 - 79 years who have not been given a shingles vaccine (NB. Individuals aged 70-79 years before 01 September 2023 are eligible until their 80th birthday)	No	Continue to use Zostavax® whilst stocks last Once Zostavax® stocks are depleted use Shingrix®. The second dose should be given 6-12 months after the first dose^^^	
50 years and over (no upper age limit)^^^	Yes^^^	Given on or after their 50th birthday	Between 8 weeks and 6 months following first dose
^ In instances where an individual	^^ Where an individual has	^^^ The catch up of the	^^^ Individuals who should

References

has already attained or passed

the age of 65 but not yet 80

for phase one then general

practices can accommodate

opportunistic vaccination if

operationally possible

 JCVI (2019) Minutes of JCVI meetings: www.gov.uk/ government/groups/joint-committee-on-vaccination-andimmunisation#minutes

turned 80 years of age

complete the course

following their first dose of

individual's 81st birthday to

should be provided before the

Shingrix®, a second dose

 Welsh Health Circular (2023) 024 Change of vaccine and cohort expansion for shingles vaccination programme (from September 2023) www.gov.wales/changes-shingles-vaccinationsseptember-2023-whc2023024

To note:

immunosuppressed group

(aged 50 years plus) should

be prioritised in the first 12

months (September 2023

- September 2024) of the

programme change

Supplies of Zostavax® are being run down as it is no longer being manufactured. Please refer to Welsh Health Circular (2023) 024 Change of vaccine and cohort expansion for shingles vaccination programme (from September 2023) www.gov.wales/changes-shingles-vaccinations-september-2023-whc2023024

be offered Shinarix®

amongst this age group are

summarised in Shingles

chapter 28a Green Book

If you would like to order more copies of this poster or any immunisation publications please visit: https://phw.nhs.wales/services-and-teams/health-information-resources

What's new?

From 1st September 2023 the NHS Wales shingles vaccination programme is introducing:

- Change of vaccine to those newly eligible for shingles vaccination
- Changes to age of eligibility

These changes are based on advice from the Joint Committee on Vaccination and Immunisation (JCVI)¹

What do I need to know?

From 1st September 2023: Phase one

- Individuals who are newly eligible for shingles vaccination should receive two doses of Shingrix®
- Age of eligibility will be extending:
 - Immunocompetent individuals

 the planned changes will be implemented in two catch-up phases over a 10-year period.
 Individuals will become eligible for Shingrix® at 65 years and 70 years in the first phase of the catch-up
 - o Immunocompromised (severely immunosuppressed) individuals will become eligible at 50 years and there is no upper age limit. The catch up of this group (aged 50 years plus) should be prioritised in the first 12 months (01 September 2023 31 August 2024)

Please refer to the **Welsh Health Circular (2023) 024**² for further details on implementation of changes to the programme.

Further information:

Green Book chapter 28a: www.gov.uk/government/publications/shingles-herpes-zoster-the-green-book-chapter-28a

Public Health Wales – Immunisation and vaccines (microsite for public and health professional information and resources) https://phw.nhs.wales/vaccines

Electronic Medicines Compendium UK – Summary of product characteristics (SmPC):

- a. Zostavax® www.medicines.org.uk/emc
- b. Shingrix® www.medicines.org.uk/emc